Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| MBS-K028 | Human | Human TROP-2-coupled Magnetic Beads |
|
||
| TR2-C52H4 | Canine | Canine TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
| TR2-R52H3 | Rhesus macaque / Cynomolgus | Rhesus macaque / Cynomolgus TROP-2 / TACSTD2 Protein, His Tag (MALS verified) |  |
|
|
| TR2-M52H6 | Mouse | Mouse TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
| TR2-H5253 | Human | Human TROP-2 / TACSTD2 Protein, Fc Tag |  |
|
|
| TR2-H82E5 | Human | Biotinylated Human TROP-2 / TACSTD2 Protein, His,Avitag™ |  |
|
|
| TR2-H5223 | Human | Human TROP-2 / TACSTD2 Protein, His Tag |  |
|
|
Immobilized Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
The purity of Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) was more than 85% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.
Immobilized Rhesus macaque / Cynomolgus TROP-2, His Tag (Cat. No. TR2-R52H3) at 1 μg/mL (100 μL/well) can bind Mouse Monoclonal Antibody Against Human TROP-2, Mouse IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Sacituzumab govitecan | IMMU-132; TROP-2-SN-38 | Approved | Immunomedics Inc | Trodelvy | United States | Carcinoma, Transitional Cell | Immunomedics Inc | 2020-04-22 | Glioblastoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Endometrial Neoplasms; Metastatic breast cancer; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Solid tumours; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Liver Failure; Ovarian Neoplasms | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| DAC-002 | DAC-002; JS-108 | Phase 1 Clinical | Hangzhou Dac Biotech Co Ltd | Solid tumours; Triple Negative Breast Neoplasms | Details |
| BAT8003 | BAT-8003 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Carcinoma, Transitional Cell | Details |
| SKB-264 | SKB-264 | Phase 2 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| 重组人源化抗Trop2单抗-SN38偶联物 | Phase 1 Clinical | Shanghai Shijian Biotechnology Co Ltd, Tot Biopharm Co Ltd | Solid tumours | Details | |
| ESG-401 | Phase 2 Clinical | Shanghai Shijian Biotechnology Co Ltd | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details | |
| Datopotamab deruxtecan | DS-1062a; DS-1062; Dato-DXd | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.
A-Z